RelA Antibodies

Santa Cruz Biotechnology features a diverse variety of RelA Antibodies for research focused on understanding the NF-κB signaling pathway. RelA monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). RelA, also known as p65, functions as a critical component of the NF-κB transcription factor complex, playing a vital role in regulating immune responses, inflammation, and cell survival. Dysregulation of RelA has been implicated in various diseases, including cancer and autoimmune disorders, making it a significant target for therapeutic intervention. Understanding the function and regulation of RelA is essential for elucidating the mechanisms underlying these pathologies. RelA monoclonal antibodies enable detailed investigation of protein-protein interactions within the NF-κB pathway. Advanced visualization techniques using RelA monoclonal antibodies allow researchers to track protein localization and expression patterns in various cellular compartments. Studying RelA activation and regulation provides valuable insights into cellular signaling mechanisms and potential therapeutic targets. Santa Cruz Biotechnology monoclonal antibodies for RelA support researchers worldwide in advancing our understanding of cellular signaling pathways and disease mechanisms.